SEO-Guangchen Pharmaceutical_Raw materials

Recently, Hubei Guangchen Pharmaceutical Co., Ltd. successfully obtained Level 2 (Managed) certification under the Data Management Capability Maturity Model (DCMM), signifying that the company has established a standardized data management system and possesses foundational data management capabilities. Moving forward, the company will deepen the integration of data with business functions such as quality control, production management, safety management, human resources, and corporate decision-making, thereby providing robust data support for the enterprise’s sustained, high-quality development.

隐藏域元素占位

Hubei Guangchen Pharmaceutical Co., Ltd. Held a Grand 2025 Work Summary Conference

On January 18, 2026, Comrade Chen Shaoyan, General Manager of the company, chaired the 2025 Work Summary Meeting of Hubei Guangchen Pharmaceutical Co., Ltd. in the company’s second-floor conference room. The meeting was attended by the company’s shareholders and management personnel at or above the department head level. During the meeting, heads of various departments gave a comprehensive summary of their respective departments’ achievements in 2025, identified existing problems, and proposed improvement measures. General Manager Comrade Chen Shaoyan then laid out the company’s key tasks for 2026 in detail.

隐藏域元素占位

Breaking into the billion-dollar diabetes market! Hubei Guangchen secures the first generic version of linagliptin-metformin extended-release tablets.

On October 28, 2025, according to an announcement on the official website of the NMPA, the Lixagliptin-Metformin Extended-Release Tablets submitted by Hubei Guangchen Pharmaceutical Co., Ltd. have been approved for marketing (Approval Number: National Drug Approval No. H20255813), making it the first generic version of this dosage form in China. This approval fills a significant gap in the Chinese market for this extended-release formulation and is expected to provide type 2 diabetes patients with a more convenient medication option.

隐藏域元素占位

Hubei Guangchen Pharmaceutical Co., Ltd. held a 2025 first-half work summary meeting

On July 25, 2025, Hubei Guangchen Pharmaceutical Co., Ltd. held a 2025 first-half work summary meeting. The meeting was presided over by General Manager Chen Shaoyan, and all members of the company's board of directors and managers at the director level and above attended the meeting. Team leaders were also in attendance.

隐藏域元素占位

The Unveiling Ceremony for the Yichang Key Laboratory of Green Pharmaceutical Manufacturing was Held

The unveiling ceremony for the Yichang Key Laboratory of Green Manufacturing of Pharmaceuticals was held at the R&D center of Hubei Guangchen Pharmaceutical Co., Ltd. on June 6, 2025.

隐藏域元素占位

(Flash) Chairman Lei Shaoqing and General Manager Chen Shaoyan of the company visited the South Korean market.

From April 20 to 25, 2025, Mr. Lei Shaoqing, Chairman of the Board, and Mr. Chen Shaoyan, General Manager, along with Ms. Zhang Hua, Director of Quality, and Mr. Zou Rui, Minister of Safety and Environmental Protection, visited KUKJEON Pharmaceutical Co., Ltd., a South Korean client, for a five-day inspection of the sales situation of Guangchen products in the South Korean market. Through in-depth exchanges with clients and visits to downstream clients, both sides clarified the key points of their next cooperation, and both expressed their willingness to maintain stable cooperation and further expand market share.

隐藏域元素占位

Carefully develop drugs with special indications using proprietary technology

Customer Service Hotline

0717-6275656

Official website: www.hbgcyy.cn
Address: No. 19, Biopark 2nd Road, Biopark Industrial Park, High-tech Zone, Yichang City.

Online consultation

SEO tags　Business License

This website supports both IPV4 and IPV6 access.